RESUMO
Anaemia is defined by the presence of haemoglobin (Hb) levels < 13 g/dL in men and 12 g/dL in women. Up to 39% of cancer patients present it at the time of diagnosis and up to 40% have iron deficiency. Anaemia causes fatigue, functional deterioration and a reduction in the quality of life; it has also been associated with a poorer response to anti-tumour treatment and lower survival. Basic diagnostic tests for anaemia are simple and should be a routine part of clinical practice. These guidelines review the available evidence on the use of different therapies for treating anaemia: erythropoiesis-stimulating agents, iron supplements, and transfusion of blood products (AU)
Assuntos
Humanos , Neoplasias/complicações , Anemia/etiologia , Anemia/terapia , Suplementos Nutricionais , Ferro da Dieta , Transfusão de Sangue , Sociedades Médicas , Anemia/diagnóstico , EspanhaRESUMO
Anaemia is defined by the presence of haemoglobin (Hb) levels < 13 g/dL in men and 12 g/dL in women. Up to 39% of cancer patients present it at the time of diagnosis and up to 40% have iron deficiency. Anaemia causes fatigue, functional deterioration and a reduction in the quality of life; it has also been associated with a poorer response to anti-tumour treatment and lower survival. Basic diagnostic tests for anaemia are simple and should be a routine part of clinical practice. These guidelines review the available evidence on the use of different therapies for treating anaemia: erythropoiesis-stimulating agents, iron supplements, and transfusion of blood products.
Assuntos
Anemia/diagnóstico , Anemia/terapia , Hematínicos/uso terapêutico , Ferro/administração & dosagem , Neoplasias/complicações , Algoritmos , Anemia/sangue , Anemia/complicações , Anemia Ferropriva/complicações , Anemia Ferropriva/diagnóstico , Diagnóstico Diferencial , Suplementos Nutricionais/efeitos adversos , Transfusão de Eritrócitos/efeitos adversos , Transfusão de Eritrócitos/métodos , Feminino , Hematínicos/efeitos adversos , Humanos , Ferro/efeitos adversos , Masculino , Oncologia , Neoplasias/mortalidade , Qualidade de Vida , Sociedades Médicas , EspanhaRESUMO
Pegylated liposomal doxorubicin (PLD) is a drug whose use is increasingly common. It has been associated with a lower rate of haematologic and cardiac side effects than its nonencapsulated form. However, mucocutaneous toxicity is quite frequent and can be severe. Here we provide a case report of a patient who developed an intertrigolike eruption during treatment with PLD (AU)
